Merck + Absci + CCR5 Sometimes the pieces don't
Post# of 263
(Total Views: 1808)
Posted On: 08/25/2025 9:15:52 AM
Merck + Absci + CCR5
Sometimes the pieces
don't click until you zoom out:
• Absci + Caltech → HIV therapeutic vaccine project (funded by Gates, Aug '23). Patent language clearly lists CCR5 inhibitors including Leronlimab (PRO-140) as required co-agents.
• Absci + Merck → $610M collaboration; Merck can nominate up to 3 drug targets.
• CytoDyn + "undisclosed Al partner" (Mar '23) → joint development agreement on long-acting CCR5 blockers. Absci's own SEC filing confirms a new undisclosed partner signed in March.
• HIV vaccine platform (Caltech/Absci) → needs CCR5 blockade.
• HIV therapy backbone (CytoDyn) → already has validated CCR5 data.
• Absci sits in the middle → feeding Al systems with CytoDyn's dataset.
• Merck waiting with an option → three targets likely include Oncology (Keytruda + LL), HIV (Pifeltro/Delstrigo + LL), NASH (LL + Gl drug).
Forward facing truth: Absci is the Al bridge, Caltech is the academic driver, CytoDyn is the CCR5 source, and Merck is the end-game partner.
It's always been MRK. There's more ...
https://patents.justia.com/patent/20220289829
https://www.pharmaceutical-technology.com/new...c-vaccine/
(This one has never been posted ^)
https://www.reddit.com/r/LeronLimab_Times/com...e_picturel
Sometimes the pieces
don't click until you zoom out:
• Absci + Caltech → HIV therapeutic vaccine project (funded by Gates, Aug '23). Patent language clearly lists CCR5 inhibitors including Leronlimab (PRO-140) as required co-agents.
• Absci + Merck → $610M collaboration; Merck can nominate up to 3 drug targets.
• CytoDyn + "undisclosed Al partner" (Mar '23) → joint development agreement on long-acting CCR5 blockers. Absci's own SEC filing confirms a new undisclosed partner signed in March.
• HIV vaccine platform (Caltech/Absci) → needs CCR5 blockade.
• HIV therapy backbone (CytoDyn) → already has validated CCR5 data.
• Absci sits in the middle → feeding Al systems with CytoDyn's dataset.
• Merck waiting with an option → three targets likely include Oncology (Keytruda + LL), HIV (Pifeltro/Delstrigo + LL), NASH (LL + Gl drug).
Forward facing truth: Absci is the Al bridge, Caltech is the academic driver, CytoDyn is the CCR5 source, and Merck is the end-game partner.
It's always been MRK. There's more ...
https://patents.justia.com/patent/20220289829
https://www.pharmaceutical-technology.com/new...c-vaccine/
(This one has never been posted ^)
https://www.reddit.com/r/LeronLimab_Times/com...e_picturel
(2)
(0)